Article ; Online: Risk factors associated with COVID-19 in systemic lupus erythematosus: Results from a longitudinal prospective cohort.
2023 Volume 32, Issue 4, Page(s) 560–564
Abstract: Introduction: Patients with SLE (systemic lupus erythematosus) have a higher risk of infection due to dysregulated immune system as well as long-term use of immunosuppressants (IS). This could influence the risk of COVID-19 and its outcome.: Methods: ...
Abstract | Introduction: Patients with SLE (systemic lupus erythematosus) have a higher risk of infection due to dysregulated immune system as well as long-term use of immunosuppressants (IS). This could influence the risk of COVID-19 and its outcome. Methods: We conducted a longitudinal prospective study across 15 rheumatology centres during the first wave of the pandemic to understand the risk factors contributing to COVID-19 in SLE patients. During the 6 months follow-up, those who tested positive for COVID-19, their clinical course and outcome information were recorded. Results: Through the study period (April-December 2020), 36/1379 lupus patients (2.9%) developed COVID-19. On analysing the COVID-19 positive versus negative cohort during the study period, male gender (adjusted RR 3.72, 95% C.I. 1.85,7.51) and diabetes (adjusted RR 2.94, 95% C.I. 1.28, 6.79) emerged as the strongest risk factors for COVID-19, in the adjusted analysis. There was no significant influence of organ involvement, hydroxychloroquine, glucocorticoid dosage (prednisolone< 7.5 mg or ≥ 7.5 mg/day) or IS on the risk of COVID-19. There was only one death (1/36) among the lupus patients due to COVID-19. Conclusion: Traditional risk factors rather than lupus disease process or IS influenced the risk of COVID-19 in our cohort. |
|||||
---|---|---|---|---|---|---|
MeSH term(s) | Humans ; Male ; Lupus Erythematosus, Systemic/complications ; Lupus Erythematosus, Systemic/drug therapy ; Prospective Studies ; COVID-19/complications ; Longitudinal Studies ; Immunosuppressive Agents/adverse effects ; Risk Factors | |||||
Chemical Substances | Immunosuppressive Agents | |||||
Language | English | |||||
Publishing date | 2023-02-02 | |||||
Publishing country | England | |||||
Document type | Journal Article | |||||
ZDB-ID | 1154407-7 | |||||
ISSN | 1477-0962 ; 0961-2033 | |||||
ISSN (online) | 1477-0962 | |||||
ISSN | 0961-2033 | |||||
DOI | 10.1177/09612033231155837 | |||||
Shelf mark |
|
|||||
Database | MEDical Literature Analysis and Retrieval System OnLINE |
More links
Kategorien
In stock of ZB MED Cologne/Königswinter
Zs.A 3717: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (2.OG) ab Jg. 2022: Lesesaal (EG) |
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.